will accelerate the growth of the global neurostimulation devices market. For instance, in July 2021, Nevro Corp. received FDA approval for its Senza® System for the treatment of chronic pain ...

On April 3, 2025, Nevro Corp. filed a notice of data breach with the Attorney General of Texas after discovering that information in the company’s possession was subject to unauthorized access.

StockNews.com assumed coverage on shares of Nevro (NYSE:NVRO – Free Report) in a report issued on Sunday. The brokerage issued a hold rating on the medical equipment provider’s stock.

The ExaStim neurostimulator received FDA breakthrough device designation ... and sensation” in patients with chronic tetraplegia due to cervical SCI. September: Nevro earned FDA approval and began a ...

Investment analysts at StockNews.com began coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the ...

REDWOOD CITY, Calif. - Nevro Corp . (NYSE: NYSE:NVRO), a global medical device company specializing in chronic pain treatment with a current market capitalization of $123 million, released ...

In a stark reflection of investor sentiment, Nevro Corp (NYSE: NVRO) stock has plummeted to a 52-week low, reaching a price level of just $3.95.According to InvestingPro data, while the company ...

REDWOOD CITY, Calif., Sept. 19, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of ...

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors ...